榴莲视频

All drugs except one remained more expensive in the U.S.

Results of FELIX study supported obecabtagene autoleucel's recent FDA approval

Agency is evaluating the need for further regulatory action

News, features, and commentary about cancer-related issues

Benefit shown in trial of patients flagged for high risk of cardiotoxicity

Complete responses in 21% of patients treated with single-agent revumenib

News, features, and commentary about cancer-related issues

Improvements seen in pain, neuropathy, and cognitive function

Health news and commentary gathered by 榴莲视频 staff

Obecabtagene autoleucel has no requirement for a REMS program

News, features, and commentary about cancer-related issues

-- News, features, and commentary about cancer-related issues

Likelihood of severe maternal morbidity more than 20 times higher versus the general population

10% of patients in trials leading to eli-cel's approval developed MDS or AML